Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Prelude Corporation is managing 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct art units and distinct examiners. Vincent Caesar Ilagan is the busiest examiner with 1 pending office action. Because each of the 5 pending office actions is assigned to a different examiner, there is no overlap in the current prosecution workload.
Practitioners must navigate the 5 distinct art units without the benefit of shared examiner interactions. The presence of 1 pending office action under Vincent Caesar Ilagan represents the current assignment for this portfolio. Successful prosecution will require specific arguments for each of the examiners involved in the Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ILAGAN, VINCENT CAESAR | 1 | 52.2% | +64.7% |
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033054 | METHODS FOR TREATING A SUBJECT WITH LOCAL INVASIVE BREAST CANCER BASED ON PDGFRB LEVELS | TURPIN, ZACHARY MARK | 134d overdue |
| 18998333 | IDENTIFICATION AND METHODS OF TREATMENT OF BREAST CANCER | ILAGAN, VINCENT CAESAR | 3d overdue |
| 17998334 | PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17657537 | PD-L1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | AEDER, SEAN E | 44d overdue |
| 18998333 | IDENTIFICATION AND METHODS OF TREATMENT OF BREAST CANCER | ILAGAN, VINCENT CAESAR | 3d overdue |
| 17998334 | PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | JONES, DAMERON LEVEST | — |
| 17275406 | METHOD OF SELECTION FOR TREATMENT OF SUBJECTS AT RISK OF INVASIVE BREAST CANCER | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 3686 | 1 |
| 1618 | 1 |
| 1682 | 1 |
| 1642 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18998333 | IDENTIFICATION AND METHODS OF TREATMENT OF BREAST CANCER | ILAGAN, VINCENT CAESAR | 3686 | §101§103 | Final Rejection | 3d overdue | Pending | Jan 24, 2025 |
| 17998334 | PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | JONES, DAMERON LEVEST | 1618 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18033054 | METHODS FOR TREATING A SUBJECT WITH LOCAL INVASIVE BREAST CANCER BASED ON PDGFRB LEVELS | TURPIN, ZACHARY MARK | 1682 | §102§103§112 | Final Rejection | 134d overdue | Pending | Apr 20, 2023 |
| 17657537 | PD-L1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | AEDER, SEAN E | 1642 | §103 | Final Rejection | 44d overdue | Pending | Mar 31, 2022 |
| 17275406 | METHOD OF SELECTION FOR TREATMENT OF SUBJECTS AT RISK OF INVASIVE BREAST CANCER | GAO, ASHLEY HARTMAN | 1678 | §103Other | Non-Final OA | — | Pending | Mar 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrelude Corporation has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Vincent Caesar Ilagan has the most, with 1 of Prelude Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
